ArticleCureus2025
Apixaban- and Rivaroxaban-Associated Bleeding: A Retrospective Analysis Using the FDA Adverse Event Reporting System.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apixaban and rivaroxaban are two agents commonly used for anticoagulation to treat and prevent blood clots and strokes in individuals with atrial fibrillation (AF). We extracted data from the FDA Adverse Event Reporting System (FAERS) database to evaluate the reporting frequency of ocular, cerebral, gastrointestinal (GI), rectal, and renal hemorrhage, epistaxis, and hemoptysis related to apixaban and rivaroxaban from January 2012 to March 2024. We calculated relative odds ratios (RORs) with 95% confidence intervals (CIs) to compare the hemorrhagic risk profiles of the two agents. There was no statistical significance in reported cases of ocular hemorrhage in apixaban versus rivaroxaban. Based on RORs, rivaroxaban overall has a significantly higher risk of bleeding in multiple organ systems - especially cerebral, GI, rectal, and renal hemorrhage, as well as epistaxis and hemoptysis. Apixaban may be a safer option for individuals at risk for, or with a history of, these complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.